These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17022049)

  • 1. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study.
    Buadi FK; Heyman MR; Gocke CD; Rapoport AP; Hakimian R; Bartlett ST; Sarkodee-Adoo C
    Am J Hematol; 2007 Mar; 82(3):208-14. PubMed ID: 17022049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
    Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
    Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
    Ghobrial IM; Habermann TM; Maurer MJ; Geyer SM; Ristow KM; Larson TS; Walker RC; Ansell SM; Macon WR; Gores GG; Stegall MD; McGregor CG
    J Clin Oncol; 2005 Oct; 23(30):7574-82. PubMed ID: 16186599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.
    Choquet S; Oertel S; LeBlond V; Riess H; Varoqueaux N; Dörken B; Trappe R
    Ann Hematol; 2007 Aug; 86(8):599-607. PubMed ID: 17522862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant lymphoproliferative disorder.
    Everly MJ; Bloom RD; Tsai DE; Trofe J
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
    Gallego S; Llort A; Gros L; Sanchez de Toledo J; Bueno J; Moreno A; Nieto J; Sanchez de Toledo J
    Pediatr Transplant; 2010 Feb; 14(1):61-6. PubMed ID: 19344338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of lymphoproliferative disease after liver transplantation.
    Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
    Marino D; Burra P; Boccagni P; Calabrese F; Canova F; Trentin C; Boso C; Soldà C; Angeli P; Aversa SM
    Anticancer Res; 2010 Jun; 30(6):2383-91. PubMed ID: 20651397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset post-transplant lymphoproliferative disease is associated with allograft localization.
    Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ; Homan van der Heide JJ; Veeger NJ; Kluin PM; Kluin-Nelemans HC
    Clin Transplant; 2005 Jun; 19(3):327-34. PubMed ID: 15877793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients.
    Raj R; Frost AE
    J Heart Lung Transplant; 2005 Jun; 24(6):671-9. PubMed ID: 15949726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.